603939.SH
益丰药房
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 23.65
−1.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 24.5B | 24.4B | 24.1B | 22.6B | 19.9B |
| Cost of Revenue | 14.8B | 14.8B | 14.4B | 14.0B | 12.0B |
| Gross Profit | 9.7B | 9.6B | 9.7B | 8.6B | 7.9B |
| Operating Expenses | |||||
| R&D Expense | 26.9M | 27.9M | 33.9M | 33.5M | 25.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.2B | 1.2B | 1.1B | 962.4M | 904.1M |
| Selling & Marketing Expense | 5.8B | 5.9B | 6.2B | 5.5B | 4.9B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 7.3B | 7.3B | 7.6B | 6.7B | 6.0B |
| Cost and Expenses | 22.1B | 22.1B | 22.0B | 20.6B | 18.0B |
| Operating Income (EBIT) | 2.5B | 2.5B | 2.2B | 2.1B | 1.9B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.5B | 2.5B | 2.2B | 2.0B | 1.9B |
| Income Tax Expense | 648.6M | 625.4M | 529.7M | 456.7M | 454.1M |
| Bottom Line | |||||
| Net Income | 1.7B | 1.7B | 1.5B | 1.4B | 1.3B |
| Earnings from Cont. Ops | 1.9B | 1.8B | 1.7B | 1.6B | 1.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.7B | 1.7B | 1.5B | 1.4B | 1.3B |
| Per Share | |||||
| Basic EPS | CN¥1.42 | CN¥1.38 | CN¥1.26 | CN¥1.17 | CN¥1.26 |
| Diluted EPS | CN¥1.42 | CN¥1.36 | CN¥1.24 | CN¥1.17 | CN¥1.25 |
| Revenue Per Share | CN¥20.12 | CN¥20.09 | CN¥19.83 | CN¥18.72 | CN¥19.86 |
| Shares | |||||
| Basic Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.0B |
| Diluted Shares Outstanding | 1.2B | 1.2B | 1.2B | 1.2B | 1.0B |
| Profitability Metrics | |||||
| EBITDA | — | 3.0B | 2.7B | 2.5B | 2.2B |
| D&A | — | 500.7M | 536.5M | 401.5M | 332.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026